ALK, ROS, c-Met

preview_player
Показать описание
ALK, ROS, c-Met
к.м.н. Д.Л. Строяковский (Москва)
  1. RosOncoWeb
  2. онкология
  3. немелкоклеточный рак легкого
  4. НМРЛ
  5. молекулярно-направленное лечение
  6. ALK
Рекомендации по теме
ALK, ROS, c-Met 0:20:56

ALK, ROS, c-Met

The Evolution of 0:04:05

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

Treatment Considerations in 0:03:55

Treatment Considerations in ALK/ROS-1–Rearranged NSCLC

2020 TTF ALK 0:25:07

2020 TTF ALK SESSION - LIN - TKIs for ROS1

Case Study: MET 0:03:52

Case Study: MET and ALK Targeted Therapies in NSCLC

ALK/ROS1-Rearranged NSCLC: Approaching 0:03:31

ALK/ROS1-Rearranged NSCLC: Approaching Therapy

Crizotinib mechanism of 0:01:51

Crizotinib mechanism of action

The therapeutic implications 0:22:21

The therapeutic implications of EML4/ALK, ROS-1 and other new biomarkers

ROS1 Rearrangements in 0:03:15

ROS1 Rearrangements in mNSCLC

Current & Emerging 0:29:51

Current & Emerging Approaches to Acquired Resistance for ALK/ROS1

Krebsmutationen: ROS1-Fusionen - 0:23:21

Krebsmutationen: ROS1-Fusionen - Wunderkerzen.

The therapeutic implications 0:22:51

The therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers

ALK Positive Lung 0:42:31

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

EML4/ALK and ROS-1: 0:21:51

EML4/ALK and ROS-1: How do we sequence therapies

The therapeutic implications 0:26:24

The therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers

Multiple Therapies Show 0:01:55

Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions

ALK and ROS1 0:40:53

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

New Ideas and 0:31:43

New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1

ROS1 ALK Initial 1:07:25

ROS1 ALK Initial Treatment, Acquired Resistance with Melina Marmarelis, MD and Charu Aggarwal, MD

ALK Inhibition in 0:08:37

ALK Inhibition in NSCLC

Gene Targeted Therapy 0:59:01

Gene Targeted Therapy for Non Small Cell Lung Cancer

MET as a 0:01:44

MET as a Secondary Driver in Lung Cancer

ASCP Project ECHO® 0:47:10

ASCP Project ECHO® Videoconference: Key Actionable Driver Mutations in Patients with Advanced NSCLC

Targeted Therapy in 0:05:53

Targeted Therapy in Non-Small Cell Lung Cancer